• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肉毒毒素治疗前疾病病程对颈肌张力障碍治疗过程和长期结局的影响。

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.

机构信息

Department of Neurology, Moorenstrasse 5, D-40225 Düsseldorf, Germany.

出版信息

Toxins (Basel). 2021 Jul 16;13(7):493. doi: 10.3390/toxins13070493.

DOI:10.3390/toxins13070493
PMID:34357965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8310129/
Abstract

This study analyses the influence of the course of the disease of idiopathic cervical dystonia (CD) before botulinum toxin (BoNT) therapy on long-term outcomes. 74 CD-patients who were treated on a regular basis in the botulinum toxin outpatient department of the University of Düsseldorf and had received at least 3 injections were consecutively recruited after written informed consent. Patients were asked to rate the amount of change of CD in relation to the severity of CD at begin of BoNT therapy (IMPQ). Then they had to draw the course of disease of CD from onset of symptoms until initiation of BoNT therapy (CoDB-graph) on a sheet of paper into a square of 10 × 10 cm size. Remaining severity of CD was estimated by the treating physician using the TSUI-score. Demographical and treatment related data were extracted from the charts of the patients. Depending on the curvature four different types of CoDB-graphs could be distinguished. Time to BoNT therapy, increase of dose and improvement during BoNT treatment were significantly ( < 0.05) different when patients were split up according to CoDB-graph types. The lower the age at onset of symptoms, the shorter was the time to therapy ( < 0.02). Initial dose ( < 0.04) and actual dose ( < 0.009) were negatively correlated with the age of the patients at recruitment. The course of disease of CD before BoNT therapy has influence on long-term outcome. This has implications on patient management and information on the efficacy of BoNT treatment.

摘要

本研究分析了特发性颈肌张力障碍(CD)患者在接受肉毒毒素(BoNT)治疗前疾病进程对长期疗效的影响。 74 名 CD 患者在杜塞尔多夫大学 BoNT 门诊接受常规治疗,且至少接受了 3 次注射后,在签署书面知情同意书后连续招募。患者被要求评估与 BoNT 治疗开始时 CD 严重程度相关的 CD 变化量(IMPQ)。然后,他们必须在一张 10×10cm 大小的纸上根据症状开始到 BoNT 治疗开始的疾病进程(CoDB-graph)绘制一个正方形。CD 的剩余严重程度由治疗医生使用 TSUI 评分进行估计。从患者图表中提取人口统计学和治疗相关数据。根据曲线的曲率,可以将 CoDB-graph 分为四种不同类型。根据 CoDB-graph 类型将患者分组后,BoNT 治疗的时间、剂量增加和治疗期间的改善均有显著差异(<0.05)。症状发作的年龄越小,治疗时间越短(<0.02)。初始剂量(<0.04)和实际剂量(<0.009)与招募时患者的年龄呈负相关。BoNT 治疗前 CD 的病程对长期疗效有影响。这对患者管理和 BoNT 治疗效果的信息具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/926d5d876dc4/toxins-13-00493-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/f61a97cc6512/toxins-13-00493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/ccaf452c01db/toxins-13-00493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/aa17dc9b492c/toxins-13-00493-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/926d5d876dc4/toxins-13-00493-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/f61a97cc6512/toxins-13-00493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/ccaf452c01db/toxins-13-00493-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/aa17dc9b492c/toxins-13-00493-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efd6/8310129/926d5d876dc4/toxins-13-00493-g004.jpg

相似文献

1
The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.肉毒毒素治疗前疾病病程对颈肌张力障碍治疗过程和长期结局的影响。
Toxins (Basel). 2021 Jul 16;13(7):493. doi: 10.3390/toxins13070493.
2
Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.从绘制疾病过程的痉挛性斜颈患者中获得的肉毒毒素 A 治疗经验:一项初步研究。
Toxins (Basel). 2023 Jun 30;15(7):431. doi: 10.3390/toxins15070431.
3
Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.探索肉毒杆菌注射治疗颈肌张力障碍的临床效果与推测效果之间的相互作用:一项初步研究。
Toxins (Basel). 2023 Sep 30;15(10):592. doi: 10.3390/toxins15100592.
4
The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation-A Monocentric Cross-Sectional Pilot Study.大剂量肉毒毒素治疗痉挛性斜颈可增加中和抗体形成风险:一项单中心横断面研究
Medicina (Kaunas). 2022 Jan 7;58(1):88. doi: 10.3390/medicina58010088.
5
The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.初始严重程度对后期结局的影响:特发性颈肌张力障碍的大样本未经肉毒毒素治疗患者的回顾性分析。
J Neurol. 2021 Jan;268(1):206-213. doi: 10.1007/s00415-020-10128-7. Epub 2020 Aug 5.
6
Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.长期肉毒毒素治疗痉挛性斜颈患者的生活质量:一项横断面研究的结果。
Parkinsonism Relat Disord. 2018 Dec;57:63-67. doi: 10.1016/j.parkreldis.2018.07.019. Epub 2018 Jul 31.
7
An analysis of the efficacy of botulinum neurotoxin type a in treating cervical dystonia.A型肉毒毒素治疗颈肌张力障碍的疗效分析。
Technol Health Care. 2024;32(4):2421-2430. doi: 10.3233/THC-231182.
8
Botulinum toxin type A and cervical dystonia: a seven-year follow-up.A型肉毒杆菌毒素与颈部肌张力障碍:七年随访
Arq Neuropsiquiatr. 2011 Oct;69(5):745-50. doi: 10.1590/s0004-282x2011000600004.
9
No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.通过绘制疾病严重程度图,证明在长效型注射用依库珠单抗的长期治疗中,无二次治疗失败。
Toxins (Basel). 2023 Jul 12;15(7):454. doi: 10.3390/toxins15070454.
10
Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A.A型肉毒毒素靶向治疗颈肌张力障碍的长期疗效。
Int J Neurosci. 2022 Oct;132(10):1026-1030. doi: 10.1080/00207454.2020.1860039. Epub 2020 Dec 17.

引用本文的文献

1
Comparison of different surgical strategies for cervical dystonia: Evidence from Bayesian network analysis.颈部肌张力障碍不同手术策略的比较:来自贝叶斯网络分析的证据。
Eur J Neurol. 2025 Jan;32(1):e16527. doi: 10.1111/ene.16527. Epub 2024 Nov 13.
2
No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.通过绘制疾病严重程度图,证明在长效型注射用依库珠单抗的长期治疗中,无二次治疗失败。
Toxins (Basel). 2023 Jul 12;15(7):454. doi: 10.3390/toxins15070454.
3
Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review.

本文引用的文献

1
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia.颈部肌张力障碍对肉毒杆菌毒素治疗反应谱的极端情况。
Toxins (Basel). 2020 Dec 31;13(1):22. doi: 10.3390/toxins13010022.
2
Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy.尽管肉毒毒素治疗后有所改善,但特发性颈部肌张力障碍仍会进展。
Front Neurol. 2020 Nov 12;11:588395. doi: 10.3389/fneur.2020.588395. eCollection 2020.
3
Botulinum toxin type A therapy for cervical dystonia.A型肉毒毒素治疗颈部肌张力障碍。
提高肉毒毒素治疗颈肌张力障碍的疗效:范围综述。
Toxins (Basel). 2023 Jun 9;15(6):391. doi: 10.3390/toxins15060391.
Cochrane Database Syst Rev. 2020 Nov 12;11(11):CD003633. doi: 10.1002/14651858.CD003633.pub4.
4
Botulinum toxin therapy of dystonia.肉毒毒素治疗肌张力障碍。
J Neural Transm (Vienna). 2021 Apr;128(4):531-537. doi: 10.1007/s00702-020-02266-z. Epub 2020 Oct 30.
5
The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.初始严重程度对后期结局的影响:特发性颈肌张力障碍的大样本未经肉毒毒素治疗患者的回顾性分析。
J Neurol. 2021 Jan;268(1):206-213. doi: 10.1007/s00415-020-10128-7. Epub 2020 Aug 5.
6
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.不同型肉毒神经毒素制剂抗原性差异的临床意义:来自我们研究资料和文献的临床启示。
Toxins (Basel). 2020 Aug 4;12(8):499. doi: 10.3390/toxins12080499.
7
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491.回复对《重新审视肉毒毒素治疗相关免疫原性》一文的评论。毒素 2019, 11, 491.
Toxins (Basel). 2020 Jan 23;12(2):72. doi: 10.3390/toxins12020072.
8
Immunogenicity Associated with Botulinum Toxin Treatment.与肉毒毒素治疗相关的免疫原性。
Toxins (Basel). 2019 Aug 26;11(9):491. doi: 10.3390/toxins11090491.
9
Update on current and emerging therapies for dystonia.肌张力障碍的现有及新出现治疗方法的最新进展
Neurodegener Dis Manag. 2019 Jun;9(3):135-147. doi: 10.2217/nmt-2018-0047. Epub 2019 May 22.
10
Remission in dystonia - Systematic review of the literature and meta-analysis.肌张力障碍缓解的系统评价文献综述和荟萃分析。
Parkinsonism Relat Disord. 2019 Sep;66:9-15. doi: 10.1016/j.parkreldis.2019.02.020. Epub 2019 Feb 16.